EUVIMEDEUVIMED entdecken
Open Access

Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

Eric D Mortenson, Yang-Xin Fu

Current Pathobiology Reports · 2013-03 · 1 (1) · 37-42

DOI: 10.1007/s40139-012-0001-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Pathobiology Reports, online erschienen am 11.12.2012. Verfasst von Eric D Mortenson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic signaling, such as HER2/neu signaling, has been shown to play major role for tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling but also shown a therapeutic advantage of its blockade. Indeed, the use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over twenty years, recent data is still uncovering new mechanisms by which this antibody exerts its anti-tumor activity. In addition to an improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, the discovery that anti-HE2/neu therapy initiates and requires the adaptive immune system is one of these new mechanisms. The presence of anti-HER2/neu initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2 positive breast cancer. This review focuses on the role of the inflammatory response in HER2 positive breast cancer with particular emphasis on trastuzumab therapy.

Schlagwörter

Stichwörter der Autor:innen

Adaptive immunityAntibody drug conjugatesAntibody therapiesBreast cancerCombination therapiesHER2/neuHerceptinImmune responsesImmunotherapyInflammationInnate immunityOncogenic signalingPathobiologyTrastuzumab

Autor:innen und Institutionen

  • Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Mortenson, E. D., & Fu, Y. X. (2013). Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports, 1(1), 37-42. https://doi.org/10.1007/s40139-012-0001-8

Vancouver

Mortenson ED, Fu YX. Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports. 2013;1(1):37-42. doi:10.1007/s40139-012-0001-8

BibTeX
@article{Mortenson2013,
  author = {Mortenson, Eric D and Fu, Yang-Xin},
  title = {Adaptive Immune Responses and HER2/neu-Positive Breast Cancer},
  journal = {Current Pathobiology Reports},
  year = {2013},
  volume = {1},
  number = {1},
  pages = {37--42},
  doi = {10.1007/s40139-012-0001-8}
}
Kostenlos starten →